INFUSYSTEM HOLDINGS, INC Operating Lease, Lease Income
INFUSYSTEM HOLDINGS, INC (INFU) reported Operating Lease, Lease Income of $7.77 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseLeaseIncome · last filed 2026-08-04
- INFUSYSTEM HOLDINGS, INC operating lease, lease income for the quarter ending 2026-06-30 was $7.77M, a 1.15% increase year-over-year.
- INFUSYSTEM HOLDINGS, INC operating lease, lease income for the quarter ending 2026-03-31 was $7.32M, a 4.96% decline year-over-year.
- INFUSYSTEM HOLDINGS, INC operating lease, lease income for the quarter ending 2025-12-31 was $7.18M, a 5.74% decline year-over-year.
- INFUSYSTEM HOLDINGS, INC operating lease, lease income for the quarter ending 2025-09-30 was $7.44M, a 2.78% increase year-over-year.
- INFUSYSTEM HOLDINGS, INC operating lease, lease income for fiscal 2025 was $30.01M, a 7.77% increase from fiscal 2024.
- INFUSYSTEM HOLDINGS, INC operating lease, lease income for fiscal 2024 was $27.84M, a 17.00% increase from fiscal 2023.
- INFUSYSTEM HOLDINGS, INC operating lease, lease income for fiscal 2023 was $23.80M, a 2.52% decline from fiscal 2022.
- INFUSYSTEM HOLDINGS, INC operating lease, lease income for fiscal 2022 was $24.41M, a 12.62% increase from fiscal 2021.
| Period end | Operating Lease, Lease Income 3 month | Operating Lease, Lease Income 6 month | Operating Lease, Lease Income 9 month | Operating Lease, Lease Income 12 month |
|---|---|---|---|---|
| 2026-06-30 | $7.77M 10-Q · filed 2026-08-04 | $15.09M 10-Q · filed 2026-08-04 | $22.27M derived: sum of 3 quarters · filed 2026-08-04 | $29.71M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $7.32M 10-Q · filed 2026-05-08 | $14.50M derived: sum of 2 quarters · filed 2026-05-08 | $21.95M derived: sum of 3 quarters · filed 2026-05-08 | $29.62M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $7.18M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $14.62M derived: sum of 2 quarters · filed 2026-02-27 | $22.30M derived: sum of 3 quarters · filed 2026-08-04 | $30.01M 10-K · filed 2026-02-27 |
| 2025-09-30 | $7.44M 10-Q · filed 2025-11-04 | $15.12M derived: sum of 2 quarters · filed 2026-08-04 | $22.82M 10-Q · filed 2025-11-04 | $30.44M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $7.68M 10-Q · filed 2026-08-04 | $15.38M 10-Q · filed 2026-08-04 | $23.00M derived: sum of 3 quarters · filed 2026-08-04 | $30.24M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $7.70M 10-Q · filed 2026-05-08 | $15.32M derived: sum of 2 quarters · filed 2026-05-08 | $22.56M derived: sum of 3 quarters · filed 2026-05-08 | $29.43M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $7.62M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $14.86M derived: sum of 2 quarters · filed 2026-02-27 | $21.73M derived: sum of 3 quarters · filed 2026-02-27 | $27.84M 10-K · filed 2026-02-27 |
| 2024-09-30 | $7.24M 10-Q · filed 2025-11-04 | $14.11M derived: sum of 2 quarters · filed 2025-11-04 | $20.23M 10-Q · filed 2025-11-04 | $26.25M derived: sum of 4 quarters · filed 2025-11-04 |
| 2024-06-30 | $6.87M 10-Q · filed 2025-08-05 | $12.98M 10-Q · filed 2025-08-05 | $19.01M derived: sum of 3 quarters · filed 2025-08-05 | $24.98M derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | $6.11M 10-Q · filed 2025-05-08 | $12.14M derived: sum of 2 quarters · filed 2025-05-08 | $18.11M derived: sum of 3 quarters · filed 2025-05-08 | $24.00M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $6.03M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $12.00M derived: sum of 2 quarters · filed 2025-03-11 | $17.89M derived: sum of 3 quarters · filed 2025-03-11 | $23.80M 10-K · filed 2025-03-11 |
| 2023-09-30 | $5.97M 10-Q · filed 2024-11-08 | $11.86M derived: sum of 2 quarters · filed 2024-11-08 | $17.77M 10-Q · filed 2024-11-08 | |
| 2023-06-30 | $5.88M 10-Q · filed 2024-08-09 | $11.79M 10-Q · filed 2024-08-09 | ||
| 2023-03-31 | $5.91M 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | $24.41M 10-K · filed 2024-04-10 | |||
| 2021-12-31 | $21.68M 10-K · filed 2024-04-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| Profound Medical Corp. (PROF) | $0.206B | -7.37 |